Abstract: Hypercholesterolemia is one of the main risk factors for the development of atherosclerosis. Decades of research have shown that lower cholesterol is better, but how low should we go? The average low-density lipoprotein cholesterol (LDL-C) level in the untreated western population is 130 mg/dl. However, insights from the early phase of life in animals and humans suggest that adult humans were genetically designed for much lower lipids level than is currently considered 'average'. Adult animals in the wild and more primitive contemporary human societies share diets that are low in fats, and have similar very low blood cholesterol levels. Furthermore, extrapolation of data from meta-analyses of large trials suggest that the incidence of cardiovascular events would approach zero if the LDL-C were <60 mg/dl in primary prevention and approximately 30 mg/dl in secondary prevention. Such goals, which are considerably lower than the recommendations in current guidelines, might be attainable with the use of newer more potent lipid-lowering therapies. To date, achieving such low lipid levels appears safe, but the generalizability of these findings to broader populations and the clinical benefit on the reduction of cardiovascular complications remains to be proven.
Introduction
One of the main risk factors for the development of coronary heart disease (CHD) and other forms of atherosclerosis is hypercholesterolemia [Stamler et al. 1986 ]. For nearly a century it has been known that animals, that normally have no atherosclerosis, develop atherosclerotic lesions when fed a cholesterol rich diet [Moghadasian, 2002] . Subsequent research into the pathophysiology of atherosclerosis has revealed mechanisms that elucidate the action of low-density lipoprotein cholesterol (LDL-C). Its oxidized form, along with proinflammatory and proapoptotic mediators produced by enzymes binding to LDL-C, play a central role in the inflammatory processes leading to the development of atherosclerotic fibroatheroma and plaque rupture [Falk, 2006] . In particular, LDL-C levels >200 mg/dl are strongly associated with a higher risk for CHD [Law and Wald, 2002] . Recent findings suggest that a large number of genes, in combination with environmental factors, such a diet, are responsible for interindividual variation in lipid levels [Pollex and Hegele, 2007] . Currently, American as well as European guidelines recommend in persons with a high risk for the development of CHD or in patients with diagnosed CHD, a LDL-C goal of less than 100 mg/dl, with an optional goal of <70 mg/dl in patients at highest risk (e.g., following an acute coronary syndrome [ACS] ) [Graham et al. 2007; Grundy et al. 2004] . However, in persons at lower risk for CHD, the LDL-C goals are considerably higher (e.g., <190 mg/dl for patients at lowest risk).
What lipid levels are physiologic?
In the western population total cholesterol (TC) has a normal distribution with an average level of 200 mg/dl (20th80th percentile: 182245 mg/dl) [Martin et al. 1986] . However, these levels should not be considered 'normal' since atherosclerosis is present in up to 50% of people by age 50 [Jaffer et al. 2002; Martin et al. 1986] . Even among apparently healthy individuals with LDL-C levels below the average (90130 mg/dl), atherosclerosis may be present [Akosah et al. 2003; Law and Wald, 2002] . Additional evidence that LDL-C levels in this range may not be optimal comes from large trials evaluating lipidlowering therapies [Sever et al. 2003; Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998; Scandinavian Simvastatin Survival Study Group, 1994] , which only reduced CHD events by one-quarter despite achieving on-treatment LDL-C levels of 88123 mg/dl. Even in clinical trials that achieved LDL-C levels well below 100 mg/dl with aggressive therapies, only one out of five clinical events were prevented with 'intensive' lipid-lowering therapy [Cannon et al. 2004] .
Since patients with LDL-C levels well below 100 mg/dl are still at risk for CHD events, the question arises: 'What lipid level is needed to reduce future CHD events to a minimum level, and is therefore seen as ''physiologic''?' Compared with humans, atherosclerosis in other mammals is not a common disease [Dietschy and Turley, 2004] . Similarly, contemporary hunter-gatherer populations that maintain a prehistoric lifestyle and diet have minimal atherosclerosis Chen et al. 1991; Sinnett and Whyte, 1973 ]. Since it is not possible to measure the lipid levels of prehistoric humans (when our diets were similar to other mammals), important comparative insights from the early period of life is helpful to estimate what lipid levels could be considered 'physiologic'. Figure 1 demonstrates the changes in TC concentration in three species (sheep, pig, and human) during the fetal, suckling, and adult periods. During brain growth in utero, when the degree of myelination and central nervous cholesterol content are rapidly changing, levels of circulating sterols show profound shifts [Dietschy and Turley, 2004] . During human fetal development both the TC and LDL-C levels decrease in late gestation reaching 55 and 30 mg/dl, respectively. A similar course is seen in sheep and pigs. In other species, an even more precipitous decline in LDL-C level to as low as 10 mg/dl has been reported [Dietschy and Turley, 2004] . During the suckling period all species show a two-to four-fold increase in TC concentration to 170 mg/dl. In breast-fed human babies, the LDL-C is 90 mg/dl. This marked increase in cholesterol after birth can be explained by the relatively large dietary cholesterol load of breast milk, which provides 18 mg cholesterol/day/kg body weight in human newborns (or approximately threequarters of the typical endogenous synthesis) [Dietschy and Turley, 2004; Wong et al. 1993] . Furthermore, a significant reduction of TC to 95 mg/dl can be achieved by substituting a low-fat, low-cholesterol formula in place of breast milk as is demonstrated by the dashed line in Figure 1 (C). These synthetic formulas provide 2 mg cholesterol/day/kg (about onetenth of the usual endogenous synthesis). After weaning, animals' TC and LDL-C fall dramatically, approaching the levels of late prenatal period. In contrast, the TC and LDL-C of most humans do not fall, likely due to the modern Western diet. Interestingly, animals weaned to much higher cholesterol and fat intake, which is similar to average human diet, also have higher TC levels (dashed lines on the right-hand side in Figure 1 ). These findings are consistent with prior laboratory studies that demonstrated that a high cholesterol diet induces atherosclerosis in many species [Moghadasian, 2002] . In contrast, animals in the wild that eat their 'typical' diet, do not have elevated TC levels or significant atherosclerosis, regardless whether these animals are carnivores (e.g., fox), omnivores (e.g., wild boar), or herbivores (e.g., elephant; Figure 2 ). In fact, the only adult mammal (with the exception of some domesticated animals) with an LDL-C level >80 mg/dl and TC >160 mg/dl is man [O' Keefe and Cordain, 2004] .
Thus, atherosclerosis may be endemic in our population largely because the LDL-C level we were 'genetically designed for' is less than half of what is presently considered 'normal'. The environment of human beings has changed profoundly within the last few thousands of years, as have the nutritional, cultural, and activity aspects of modern societies. However, there are still large groups of individuals (e.g., huntergatherer societies) with a lifestyle that is similar to prehistoric civilization of more than 10,000 years ago. In contrast to Western humans consuming 200500 mg cholesterol/day (approximately 4080% of endogenous synthesis) [Martin et al. 1986 ], these populations live on diets containing 100 mg cholesterol/day (approximately 1020% of endogenous synthesis). These populations typically have TC and LDL-C concentrations below 135 and 70 mg/dl, respectively [Dietschy and Turley, 2004; . Even among older individuals living into their seventh and eighth decades in these contemporary hunter-gatherer societies, CHD and other forms of atherosclerosis are virtually unknown Chen et al. 1991; Sinnett and Whyte, 1973] . However, if such individuals adopt a western diet, their lipids levels rapidly increase and become indistinguishable from those levels found in western population [Dietschy and Turley, 2004; McMurry et al. 1991] . In large controlled studies investigating the impact of western diets a reduction of 10 mg/dl TC occurred for every decrease of 100 mg in dietary cholesterol per 1000 kcal [Grundy et al. 1988] . More importantly, a reduction of cardiovascular events can be achieved with lipid lowering diets [Watts et al. 1992 ]. However, poor adherence to low-fat/cholesterol diets is one of the major limitations of these interventions. Furthermore, the clinical benefit of low-fat/cholesterol diets may be blunted in some patients by genetic differences that can play an important role in lipid metabolism [Pollex and Hegele, 2007] and other uncontrolled risk factors for atherosclerosis (e.g., smoking, hypertension, diabetes).
Lessons learned from nature
The available data from the early phases of life, as well as that from current hunter-gatherer populations and mammals living in the wild, suggest that the higher cholesterol level present in most modern adult humans is primarily a result of our diet rather than due to other reasons. Neither genetic variation nor other lifestyle issues are likely to explain the increase in cholesterol when individuals migrate and adopt western diets. Thus, it seems quite plausible that the LDL-C level humans were genetically designed is somewhere between 30 and 70 mg/dl. However, three major questions remain:
1. Would achieving such very low lipid goals improve clinical outcomes? 2. Is it possible to attain such very low lipid levels with current therapies? 3. Would such intensive lipid lowering be safe?
Would achieving very low lipid goals improve clinical outcomes?
With growing evidence from clinical trials that more intensive lipid lowering aiming for target LDL-C far below 100 mg/dl is more effective in reducing cardiovascular events [Graham et al. 2007; Cannon et al. 2006; Grundy et al. 2004; , current guidelines continue to lower the target LDL-C. The current American guidelines state that a LDL-C goal of <70 mg/dl is a therapeutic option in high-risk patients, and the European guidelines recommend an LDL-C goal of <97 mg/dl (2.5 mmol/l), with a further reduction to <77 mg/dl (2 mmol/l) as a reasonable option, if feasible [Graham et al. 2007; Grundy et al. 2004] .
However, some investigators argue that the optimal LDL-C level should be that level at which no clinically significant atherosclerosis develops [Law and Wald, 2002] . In fact, data from meta-analyses of randomized controlled trials of statin therapies suggest that there may be a level at which atherosclerosis can not only be slowed, but possibly even be arrested or reversed . In these meta-analyses the rate of angiographic progression of atherosclerosis was closely related to the LDL-C levels in a linear proportion, irrespective of whether patients were on statin therapy or placebo. The calculated threshold for atherosclerotic progression was found at a LDL-C level of approximately 67 mg/dl. A similar threshold (57 mg/dl) was found for primary prevention patients based on the incidence of CHD events obtained in a meta-analysis of the large CHD event reduction trials that studied >100,000 patients [O' Keefe et al. 2004] . Using data from the same meta-analysis, an even lower LDL level (30 mg/ dl) in secondary prevention was required to minimize recurrent cardiovascular events, regardless of the presence of other risk factors. Finally, an analysis from the PRavastatin Or atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial demonstrated that patients following an ACS benefited more from intensive lipid lowering than standard therapy, provided their starting LDL was more than 66 mg/dl [Giraldez et al. 2008] .
The hypothesis that ''even lower is even better'', i.e. that an LDL of 5055 mg/dl will translate into fewer cardiovascular events compared with an LDL of 6570 mg/dl, is explicitly being tested in the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) ]. This trial is randomizing 18,000 patients within 10 days of hospital admission with an ACS to ezetimibe/simvastatin 10/40 mg or simvastatin 40 mg for a minimum of 2.5 years.
Is it possible to attain such very low lipid levels with current therapies? With the advent of more potent statins and increasing utilization of combination therapies, it seems to be possible to achieve a more pronounced lipid lowering in most patients (Table 1) . For example, in the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, an open-label study randomizing 2431 stable patients (80% primary prevention) to different statin treatments, over 80% of patients receiving 4080 mg atorvastatin and over 90% receiving 2040 mg rosuvastatin reached the LDL-C goal of below 116 mg/dl (3 mmol/l) [Jones et al. 2003; Pyorala and Wood, 1998 ]. Further options to reach lower lipid goals are combined therapies of statins with other lipid-lowering drugs such as ezetimibe, niacin, or bile acid resins . However, whether such combination therapies reduce clinical events, and whether this can be achieved safely, remain to be demonstrated.
Would such an intensive lipid lowering be safe? There are two main aspects regarding safety in lipid-lowing therapies. One is obviously the potential adverse effects of the drugs used. For statins, the drug class that is most widely used and with the best evidence of reducing CHD, liver and muscle toxicity are the major adverse effects [Alsheikh-Ali et al. 2007; Kashani et al. 2006] . These side effects of statins appear to be dose related and not associated with the on-treatment LDL-C level. However, major adverse effects are rare and most patients tolerate statin therapy well, even when very low LDL-C levels are attained [Leeper et al. 2007; Wiviott et al. 2005] .
The other aspect that may affect safety is the achieved lipid level of lipid itself. As cholesterol is an indispensable molecular building block, not only for brain development as described above, but also for the fundamental structure of all animal cells, a minimum concentration of cholesterol is required for survival [Dietschy and Turley, 2004] . There may be a cholesterol level that is too low to maintain health. Indeed, several epidemiological studies have demonstrated a U-shaped relationship between all-cause mortality rates and the TC concentration, with an increase in mortality, not only at higher TC levels, but also at low levels [Iribarren et al. 1995] . However, it appears that the described epidemiologic association of lower cholesterol with higher mortality is not a causal relationship, but rather, better explained by confounding from serious underlying chronic diseases such as cancer that are more prevalent in patients with low cholesterol. Even stronger evidence that lifelong very low lipid levels are safe comes from individuals with genetic variations resulting in low TC levels. For example, LDL-C concentrations of 30 mg/dl are common in heterozygous hypobetalipoproteinemia, yet these individuals have an exceptionally long life expectancy [Glueck et al. 1997] .
Conclusions
Old conceptions regarding what constitutes a 'normal lipid level' need to be reexamined in light of new analyses from lipid levels in the early phase of life, comparisons with other mammals, and epidemiological data from contemporary hunter-gatherer populations. These data support target levels of LDL-C well below those recommended in current guidelines (i.e. 70100 mg/dl for high-risk patients). These findings are consistent with extrapolations derived from meta-analyses and recent clinical trials. The totality of the evidence to date suggests that the physiologic LDL-C level for humans may be as low as 3070 mg/dl. However, a number of questions remain. Can this LDL level be reached in most patients with currently available therapies? Are such low levels of LDL safe? Will this lower target LDL goal translate into a meaningful reduction of atherosclerotic events compared to the current targets? These are open questions for ongoing and future clinical trials.
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